J
Jürgen Klempnauer
Researcher at Hannover Medical School
Publications - 373
Citations - 13463
Jürgen Klempnauer is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 58, co-authored 367 publications receiving 12386 citations. Previous affiliations of Jürgen Klempnauer include University of Düsseldorf & Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)
René Adam,Vincent Karam,Valérie Delvart,John O'Grady,Darius F. Mirza,Jürgen Klempnauer,Denis Castaing,Peter Neuhaus,Neville V. Jamieson,Mauro Salizzoni,Stephen Pollard,Jan Lerut,Andreas Paul,Juan Carlos García-Valdecasas,Fernando San Juan Rodríguez,Andrew K. Burroughs +15 more
TL;DR: All data since 1968 are considered to show the evolu-tion of results of LT in Europe since its initial development and to demonstrate the reliability of ELTR data.
Journal ArticleDOI
Evolution of liver transplantation in Europe: Report of the European liver transplant registry
René Adam,Paul McMaster,John O'Grady,Denis Castaing,Jürgen Klempnauer,Neville V. Jamieson,Peter Neuhaus,Jan Lerut,Mauro Salizzoni,Stephen Pollard,Ferdinand Mühlbacher,Xavier Rogiers,Juan Carlos Garcia Valdecasas,Joaquín Berenguer,Daniel Jaeck,Enrique Moreno González +15 more
TL;DR: One of the most important findings in the evolution of LT is the considerable improvement of results along time with, for the mean time, a one‐year survival of 83%, all indications confounded.
Journal ArticleDOI
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.
Andrew K. Burroughs,Caroline A. Sabin,Keith Rolles,Valérie Delvart,Vincent Karam,John A. C. Buckels,John O'Grady,Denis Castaing,Jürgen Klempnauer,Neville V. Jamieson,Peter Neuhaus,Jan Lerut,Jean de Ville de Goyet,Stephen Pollard,Mauro Salizzoni,Xavier Rogiers,Ferdinand Mühlbacher,Juan Carlos Garcia Valdecasas,C. E. Broelsch,Daniel Jaeck,Joaquín Berenguer,Enrique Moreno González,R. Adam +22 more
TL;DR: The 3-month and 12-month mortality models can be effectively used to assess outcomes both within and between centres, and provide a means of assessing the risk of post-transplantation mortality, giving clinicians important data to base strategic decisions about transplant policy in particular individuals or groups.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Surgical treatment in proximal bile duct cancer. A single-center experience
Rudolf Pichlmayr,Arved Weimann,Jürgen Klempnauer,Karl J. Oldhafer,H. Maschek,G. Tusch,Burckhardt Ringe +6 more
TL;DR: Resection remains the treatment of choice in proximal bile duct carcinoma and decisions about resectability should be made during laparotomy, and liver transplantation can be justified in selected patients with stage II carcinoma.